TY - JOUR
T1 - Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies
AU - Paul, Allan J.
AU - Hutchens, Douglas E.
AU - Firkins, Lawrence D.
AU - Keehan, Coleen M.
PY - 2004/3
Y1 - 2004/3
N2 - Objective - To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose. Animals - 15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs. Procedure - Dogs were assigned to 3 treatment groups (control, 3X, or 5X group) in a randomized block design on the basis of the maximal ivermectin-sensitivity score obtained during preliminary screening. Dogs in groups 3X and 5X were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation. Results - None of the dogs had clinical abnormalities during the study period. Conclusions and Clinical Relevance - Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose.
AB - Objective - To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose. Animals - 15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs. Procedure - Dogs were assigned to 3 treatment groups (control, 3X, or 5X group) in a randomized block design on the basis of the maximal ivermectin-sensitivity score obtained during preliminary screening. Dogs in groups 3X and 5X were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation. Results - None of the dogs had clinical abnormalities during the study period. Conclusions and Clinical Relevance - Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose.
UR - http://www.scopus.com/inward/record.url?scp=1542725067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542725067&partnerID=8YFLogxK
U2 - 10.2460/ajvr.2004.65.277
DO - 10.2460/ajvr.2004.65.277
M3 - Article
C2 - 15027671
AN - SCOPUS:1542725067
SN - 0002-9645
VL - 65
SP - 277
EP - 278
JO - American journal of veterinary research
JF - American journal of veterinary research
IS - 3
ER -